Treatment for TORCH Positive Patients in Pregnancy

Toxoplasmosis Management

The American Academy of Pediatrics recommends spiramycin 1g (or 3 million IU) orally three times daily for pregnant women with suspected or confirmed toxoplasmosis before 18 weeks gestation 3, 4, 1, 2
The American Academy of Pediatrics recommends switching to combination therapy with pyrimethamine plus sulfadiazine plus folinic acid at or after 18 weeks gestation or if fetal infection is confirmed 3, 4, 1, 2
For HIV-infected pregnant women, the Centers for Disease Control and Prevention recommends TMP-SMZ for toxoplasmosis prophylaxis, though pyrimethamine-containing regimens may be deferred until after pregnancy due to teratogenicity concerns 6, 7, 1, 2

The American College of Obstetricians and Gynecologists recommends acyclovir for primary HSV infection or severe disease during pregnancy, which has no increased risk for major birth defects based on decades of safety data 1
The American College of Obstetricians and Gynecologists recommends offering antiviral prophylaxis in the third trimester to women with a history of genital herpes to reduce recurrence risk at delivery 1

The European Association for the Study of the Liver recommends starting tenofovir disoproxil fumarate at 24-28 weeks gestation and continuing until 12 weeks postpartum for pregnant women with HBV DNA >200,000 IU/ml or HBeAg-positive 8
The European Association for the Study of the Liver recommends continuing tenofovir throughout pregnancy for women with chronic HBV and advanced fibrosis/cirrhosis 8
Breastfeeding while on tenofovir is safe and should not be discouraged, according to the European Association for the Study of the Liver 8

The American Academy of Pediatrics recommends monthly fetal ultrasounds for all confirmed TORCH infections to detect developing abnormalities 3, 9, 1
The American Academy of Pediatrics recommends neonatal evaluation, including serologic testing at reference laboratories, ophthalmologic examination, neurologic assessment, and hearing evaluation, for all infants born to TORCH-positive mothers 3, 9, 1

The American Academy of Pediatrics recommends never relying on commercial laboratory IgM results alone for toxoplasmosis diagnosis—false positives are frequent and lead to unnecessary interventions 3, 5
The American Academy of Pediatrics recommends avoiding delaying spiramycin initiation while awaiting confirmatory testing if acute toxoplasmosis is clinically suspected—early treatment reduces transmission risk 3